Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: LYM118
MIFTS: 69

Lymphoma

Categories: Blood diseases, Cancer diseases, Eye diseases, Immune diseases, Neuronal diseases
Genes Variations Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Lymphoma

About this section

MalaCards integrated aliases for Lymphoma:

Name: Lymphoma 12 77 30 56 6 44 45 15 17 74
Lymphoid Neoplasm 74
Lymphoid Cancers 74
Lymphoid Cancer 12

Classifications:

MalaCards categories:
Global: Cancer diseases
Anatomical: Blood diseases Eye diseases Neuronal diseases Immune diseases
See all MalaCards categories (disease lists)
ICD10: 34


External Ids:

Disease Ontology 12 DOID:0060058
MeSH 45 D008223
NCIt 51 C3208 C7065
SNOMED-CT 69 21964009
ICD10 34 C85.9
Sources

Summaries for Lymphoma

About this section
MedlinePlus : 44 Lymphoma is a cancer of a part of the immune system called the lymph system. There are many types of lymphoma. One type is Hodgkin disease. The rest are called non-Hodgkin lymphomas. Non-Hodgkin lymphomas begin when a type of white blood cell, called a T cell or B cell, becomes abnormal. The cell divides again and again, making more and more abnormal cells. These abnormal cells can spread to almost any other part of the body. Most of the time, doctors don't know why a person gets non-Hodgkin lymphoma. You are at increased risk if you have a weakened immune system or have certain types of infections. Non-Hodgkin lymphoma can cause many symptoms, such as Swollen, painless lymph nodes in the neck, armpits or groin Unexplained weight loss Fever Soaking night sweats Coughing, trouble breathing or chest pain Weakness and tiredness that don't go away Pain, swelling or a feeling of fullness in the abdomen Your doctor will diagnose lymphoma with a physical exam, blood tests, a chest x-ray, and a biopsy. Treatments include chemotherapy, radiation therapy, targeted therapy, biological therapy, or therapy to remove proteins from the blood. Targeted therapy uses substances that attack cancer cells without harming normal cells. Biologic therapy boosts your body's own ability to fight cancer. If you don't have symptoms, you may not need treatment right away. This is called watchful waiting. NIH: National Cancer Institute

MalaCards based summary : Lymphoma, also known as lymphoid neoplasm, is related to follicular lymphoma and lymphoma, mucosa-associated lymphoid type. An important gene associated with Lymphoma is PMS2 (PMS1 Homolog 2, Mismatch Repair System Component), and among its related pathways/superpathways are MicroRNAs in cancer and Prolactin Signaling Pathway. The drugs Tenofovir and rituximab have been mentioned in the context of this disorder. Affiliated tissues include b cells, t cells and bone, and related phenotypes are cellular and hematopoietic system

Disease Ontology : 12 A hematologic cancer that affects lymphocytes that reside in the lymphatic system and in blood-forming organs.

Wikipedia : 77 Lymphoma is a group of blood cancers that develop from lymphocytes (a type of white blood cell). The... more...

Sources

Related Diseases for Lymphoma

About this section

Diseases in the Lymphoma family:

Adult Lymphoma Eye Lymphoma

Diseases related to Lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1899)
# Related Disease Score Top Affiliating Genes
1 follicular lymphoma 35.0 BCL10 BCL2 BCL6 CCND1 MYC
2 lymphoma, mucosa-associated lymphoid type 34.8 BCL10 BCL2 BCL6 CCND1 CXCR5 MALT1
3 diffuse large b-cell lymphoma 34.8 BCL10 BCL6 MALT1 MYC
4 lymphoma, hodgkin, classic 34.7 ALK BCL6 PVT1
5 primary effusion lymphoma 34.6 BCL6 MYC TCL1A
6 gastric lymphoma 34.6 BCL10 BCL2 BCL6
7 lymphoma, non-hodgkin, familial 34.6 ALK ATM BCL10 BCL2 BCL6 CCND1
8 peripheral t-cell lymphoma 34.6 ALK BCL6 TCL1A
9 follicular lymphoma 1 34.6 BCL10 BCL2 BCL6
10 burkitt lymphoma 34.6 BCL2 BCL6 BCL7A CXCR5 MYC PVT1
11 marginal zone b-cell lymphoma 34.4 BCL10 BCL2 BCL6 CCND1 MALT1
12 mantle cell lymphoma 34.2 ATM BCL2 BCL6 CCND1 GAS5 MALT1
13 lymphoma, small cleaved-cell, diffuse 34.2 BCL2 CCND1
14 alk-negative anaplastic large cell lymphoma 34.2 ALK BCL2 MYC
15 nodal marginal zone b-cell lymphoma 34.1 BCL2 BCL6 MALT1
16 lung lymphoma 34.1 ALK BCL6 MALT1
17 primary cutaneous marginal zone b-cell lymphoma 34.1 BCL10 MALT1
18 intravascular large b-cell lymphoma 34.0 BCL2 BCL6
19 primary cutaneous cd4+ small/medium-sized pleomorphic t-cell lymphoma 34.0 BCL6 CXCR5
20 diffuse large b-cell lymphoma of the central nervous system 34.0 BCL2 MYC
21 primary mediastinal large b-cell lymphoma 33.8 BCL6 MYC
22 b-cell lymphomas 33.7 BCL10 BCL2 BCL6 CCND1 GAS5 MALT1
23 high grade b-cell lymphoma with myc and/ or bcl2 and/or bcl6 rearrangement 33.6 BCL2 BCL6 MYC
24 acute t cell leukemia 33.1 BCL10 BCL11B TCL6
25 precursor t-cell acute lymphoblastic leukemia 32.9 BCL10 MYC TCL1A
26 leukemia, chronic lymphocytic 32.6 ATM BCL10 BCL2 BCL6 CCND1 CXCR5
27 t-cell leukemia 31.6 ATM BCL11B GAS5 MYC TCL1A TCL6
28 autoimmune lymphoproliferative syndrome, type v 31.4 ALK BCL2 BCL6 TCL1A
29 lymphocytic leukemia 31.0 ATM BCL2 DLEU2 MYC PTPN11
30 chromosomal triplication 30.8 BCL6 MALT1
31 prolymphocytic leukemia 30.8 ATM CCND1 MYC TCL1A
32 t-cell prolymphocytic leukemia 30.6 ATM MYC TCL1A
33 myeloma, multiple 30.5 CCND1 GAS5 MYC PTPN11 PVT1
34 intestinal disease 30.4 BCL6 CCND1 MYC PMS2
35 nasopharyngeal carcinoma 30.4 BCL2 CCND1 GAS5 MYC PVT1
36 glioma 29.9 BCL2 CCND1 GAS5 PVT1
37 ovarian cancer 29.8 ATM BCL2 CCND1 GAS5 MYC PVT1
38 gastric cancer 29.7 BCL2 CCND1 GAS5 MYC PVT1 SNHG5
39 cervical cancer 29.6 BCL2 CCND1 GAS5 MYC PVT1
40 endometrial cancer 29.4 BCL2 CCND1 GAS5 MYC PMS2
41 synchronous bilateral breast carcinoma 29.3 ATM CCND1
42 hematologic cancer 29.2 ALK ATM BCL6 MYC PTPN11 PVT1
43 brain cancer 29.1 ALK MYC PMS2 PTPN11
44 bladder cancer 29.0 CCND1 GAS5 MYC PVT1 SNHG5
45 large intestine cancer 28.9 CCND1 MYC PMS2 PTPN11
46 colorectal cancer 28.9 BCL10 BCL2 CCND1 GAS5 MYC PMS2
47 anaplastic large cell lymphoma 12.6
48 primary central nervous system lymphoma 12.6
49 intraocular lymphoma 12.5
50 plasmablastic lymphoma 12.5

Graphical network of the top 20 diseases related to Lymphoma:



Diseases related to Lymphoma
Sources

Symptoms & Phenotypes for Lymphoma

About this section

MGI Mouse Phenotypes related to Lymphoma:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.17 ATM BCL10 BCL11B BCL2 BCL6 CCND1
2 hematopoietic system MP:0005397 10.11 ATM BCL10 BCL11B BCL2 BCL6 CCND1
3 endocrine/exocrine gland MP:0005379 10.1 ALK ATM BCL10 BCL11B BCL2 BCL6
4 immune system MP:0005387 10.06 ATM BCL10 BCL11B BCL2 BCL6 CCND1
5 mortality/aging MP:0010768 9.93 ALK ATM BCL10 BCL11B BCL2 BCL6
6 integument MP:0010771 9.8 ALK ATM BCL11B BCL2 CCND1 MYC
7 neoplasm MP:0002006 9.61 ALK ATM BCL11B BCL2 CCND1 MYC
8 reproductive system MP:0005389 9.28 ALK ATM BCL2 BCL6 CCND1 MYC
Sources

Drugs & Therapeutics for Lymphoma

About this section

Drugs for Lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1063)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Tenofovir Approved, Experimental, Investigational Phase 4,Phase 3,Phase 2,Phase 1 147127-20-6 464205
2
rituximab Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 174722-31-7 10201696
3
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 302-25-0
4
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 53-03-2 5865
5
Vinblastine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 865-21-4 241903 13342
6
Methylprednisolone hemisuccinate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 2921-57-5
7
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-24-8 5755
8
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 83-43-2 6741
9
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 50-18-0, 6055-19-2 2907
10
Gemcitabine Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 95058-81-4 60750
11
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 23214-92-8 31703
12
Epirubicin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 56420-45-2 41867
13
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 1177-87-3
14
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 50-02-2 5743
15
Etoposide Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 33419-42-0 36462
16
Vincristine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 2068-78-2, 57-22-7 5978
17
Oxaliplatin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 61825-94-3 43805 6857599 5310940 9887054
18
Cytarabine Approved, Experimental, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 147-94-4, 65-46-3 6253
19
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 15663-27-1 2767 441203 84093
20
Methotrexate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 1959-05-2, 59-05-2 126941
21
Mechlorethamine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 51-75-2 4033
22
Ifosfamide Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 3778-73-2 3690
23
Pegaspargase Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 130167-69-0
24
Mesna Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 3375-50-6 598
25
Ferrous succinate Approved Phase 4 10030-90-7
26
Hydroxocobalamin Approved Phase 4,Phase 3,Phase 2,Phase 1 13422-51-0 15589840 11953898
27
Methylcobalamin Approved, Experimental, Investigational Phase 4,Phase 3,Phase 2,Phase 1 13422-55-4
28
Iron Approved, Experimental Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1 7439-89-6, 15438-31-0 27284 23925
29
leucovorin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 58-05-9 143 6006
30
Entecavir Approved, Investigational Phase 4,Phase 2,Not Applicable 142217-69-4 153941
31
Aprepitant Approved, Investigational Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1 170729-80-3 6918365 151165
32
Fosaprepitant Approved Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1 172673-20-0 219090
33
Amoxicillin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 26787-78-0 33613
34
Metronidazole Approved Phase 4,Phase 3,Phase 2 443-48-1 4173
35
Clarithromycin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 81103-11-9 84029
36
Tropisetron Approved, Investigational Phase 4,Not Applicable 105826-92-4, 89565-68-4 5595
37
Fludarabine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 75607-67-9, 21679-14-1 30751
38
Daunorubicin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 20830-81-3 30323
39
Thioguanine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 154-42-7 2723601
40
Mercaptopurine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 50-44-2 667490
41
Dasatinib Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 302962-49-8 3062316
42
Idarubicin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 58957-92-9 42890
43
Teniposide Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 29767-20-2 34698
44
Vindesine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 53643-48-4, 59917-39-4 40839
45
Cladribine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 4291-63-8 20279
46
Sargramostim Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 123774-72-1, 83869-56-1
47
Lenograstim Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 135968-09-1
48
Denileukin diftitox Approved, Investigational Phase 4,Phase 2,Phase 1,Not Applicable 173146-27-5
49
Bexarotene Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 153559-49-0 82146
50
Vidarabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 24356-66-9 21704 32326

Interventional clinical trials:

(show top 50) (show all 6944)
# Name Status NCT ID Phase Drugs
1 To Compare the Efficacy of a Prophylactic Use of Tenofovir by Duration for the Non-Hodgkin's Lymphoma Unknown status NCT02585947 Phase 4 Tenofovir
2 Surgery Alone, Surgery With Cyclophosphamide, Vinblastine, and Prednisolone (CVP), or CVP Alone in Treating Young Patients With Stage IA or Stage IIA Nodular Lymphocyte-Predominant Hodgkin Lymphoma Unknown status NCT01088750 Phase 4 cyclophosphamide;prednisolone;vinblastine sulfate
3 PEG-rhG-CSF in Patients With Non-Hodgkin Lymphoma Receiving Chemotherapy to Prevent Neutropenia Unknown status NCT02996617 Phase 4 rhG-CSF regimen;Pegylated rhG-CSF regimen
4 PEG-rhG-CSF in Lymphoma Patients After Autologous Hematopoietic Stem Cell Transplantation Unknown status NCT02905942 Phase 4 PEG-rhG-CSF;rhG-CSF
5 Treatment of Natural Killer/T Cell Lymphoma-I/II Unknown status NCT01501136 Phase 4
6 Treatment of Natural Killer/T Cell Lymphoma-Ⅲ/Ⅳ Unknown status NCT01501149 Phase 4 DDGP(cisplatin,dexamethasone,gemcitabine,pegaspargase);Modified SMILE （MTX，DEX，IFO，L-ASP，Etoposide，Mesna）
7 Treatment of Diffuse Large B Cell Lymphoma Unknown status NCT01949818 Phase 4 Yangzhengxiaoji capsule combined with CHOP regimen;CHOP regimen
8 Erythropoietin in the Treatment of Anemia After Autologous Hematopoietic Stem Cell Transplantation Unknown status NCT03010579 Phase 4 erythropoietin;iron supplementation
9 Intensification Therapy of Mature B-ALL, Burkitt and Burkitt Like and Other High Grade Non-Hodgkin's Lymphoma in Adults Unknown status NCT00797810 Phase 4 Rituximab
10 Prophylactic Use of Entecavir for HBsAg Negative/HBcAb Positive/Hepatitis B Virus DNA Negative Patients With Lymphoma Unknown status NCT01765231 Phase 4 Entecavir prophylaxis;Observation arm
11 Prophylactic Use of Entecavir for HBsAg Positive Lymphoma Patients Treated With Rituximab-based Immunochemotherapy Unknown status NCT01768195 Phase 4 Entecavir prophylaxis
12 Low Grade Lymphoma Unknown status NCT01698866 Phase 4
13 CEOP/IVE/GDP Compared With CEOP as the First-line Therapy for Newly Diagnosed Adult Patients With PTCL Unknown status NCT02533700 Phase 4 CEOP/IVE/GDP chemotherapy regimen;CEOP chemotherapy regimen for 6 cycles
14 Optimization of the Primary Therapy for Patients With Hodgkin's Disease and Evaluation of PET Unknown status NCT00188149 Phase 4 Combined chemotherapy (ABVD, BACOPP-D)
15 Study of Standard and Individualized Treatment Model for Relapse and Refractory Lymphatic System Malignant Tumors Unknown status NCT02929615 Phase 4
16 Self-control Trial to Evaluate the Role of Aprepitant in the Prophylaxis of Post-lumbar-punture-headache (PLPH) Unknown status NCT02347878 Phase 4 Aprepitant
17 Study Comparing Sequential and Concomitant Therapy for Helicobacter Pylori Eradication in Routine Clinical Practice Unknown status NCT01273441 Phase 4 PPI, amoxicillin, metronidazole and clarithromycin;PPI, amoxicillin, metronidazole and clarithromycin
18 The Efficacy and Safety of PEG-rhG-CSF in Neutropenia After Chemotherapy Unknown status NCT02905916 Phase 4 PEG-rhG-CSF
19 A Study Evaluating the Efficacy and Safety of Aprepitant in Autologous Hematopoietic Stem Cell Transplantation Unknown status NCT02576327 Phase 4 Tropisetron;Dexamethasone;Aprepitant
20 Malaysia-Singapore Acute Lymphoblastic Leukemia 2010 Study Unknown status NCT02894645 Phase 4 Prednisolone;Dexamethasone;L-Asparaginase;Vincristine;Methotrexate;Daunorubicin;Doxorubicin;Cyclophosphamide;Cytarabine;6-Mercaptopurine;Thioguanine;Fludarabine;Imatinib
21 Low-dose Chemotherapy Combine With Tyrosine Kinase Inhibitor to Treat ph+ Acute Lymphoblastic Leukemia Patients Unknown status NCT02690922 Phase 4 Dasatinib;prednisone;dexamethasone;methotrexate
22 HD-Idarubicin/Etoposide Intensified Conditioning Regimen Allo-HSCT for Adult ALL Unknown status NCT01873807 Phase 4 IDA;CTX;VP-16
23 The GD-2008 ALL Protocol for Childhood Acute Lymphoblastic Leukemia Unknown status NCT00846703 Phase 4 6-mercaptopurine, Methotrexate;6-mercaptopurine, Methotrexate, Vincristine, Dexamethasone
24 Medical Research Council (MRC) Working Party on Leukaemia in Children UK National Acute Lymphoblastic Leukaemia (ALL) Trial: UKALL 2003 Unknown status NCT00222612 Phase 4 Standard childhood UK ALL protocol;Intensified treatment including Capizzi maintenance
25 Poly(Ethylene Glycol)(PEG)-Asparaginase During Two Treatment Courses Unknown status NCT00192673 Phase 4 PEG-asparaginase
26 German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (07/2003) Unknown status NCT00198991 Phase 4 Cyclophosphamide;Dexamethasone;Vincristine;daunorubicin;Asparaginase;Methotrexate;Cytarabine;Mercaptopurine;G-CSF;Vindesine;VP16;Prednisolone;Adriamycin;Thioguanine;VM26;Idarubicin;Fludarabine;Cladribine
27 German Multicenter Trial for Treatment of Elderly Patients With Newly Diagnosed Acute Lymphoblastic Leukemia Unknown status NCT00198978 Phase 4 Cyclophosphamide;Dexamethasone / Prednisolone;Cytarabine;Idarubicin;Granulocyte-Colony-Stimulating Factor;Mercaptopurine;Methotrexate;Rituximab;HDARAC;Vincristine;Depocyte;Asparaginase
28 Treatment Protocol of Children With Philadelphia Chromosome Negative High Risk Acute Lymphoblastic Leukemia Unknown status NCT01990807 Phase 4 Idarubicin(IDA)
29 Relationship Between Platinum Levels in the Blood and Neurotoxicity in Patients Who Are Receiving Oxaliplatin for Gastrointestinal Cancer Unknown status NCT00274885 Phase 4 oxaliplatin
30 Zevalin® Followed by Rituxan® Maintenance in Previously Treated Low Grade Non-Hodgkin’s Lymphoma Completed NCT00168727 Phase 4 ibritumomab tiuxetan (Zevalin®)
31 Apatinib for Relapsed and Refractory Diffuse Large B Cell Lymphoma Completed NCT03376958 Phase 4 Apatinib
32 Treatment of Peripheral T-cell Lymphoma Completed NCT01664975 Phase 4 GDPT regimen;CHOP regimen
33 PEG-rhG-CSF in Patients With Lymphoma Receiving Chemotherapy Completed NCT02805218 Phase 4 PEG-rhG-CSF
34 MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma. Completed NCT00430352 Phase 4 rituximab [MabThera/Rituxan]
35 Study of ONTAK® to Treat Cutaneous T-Cell Lymphoma (CTCL) Completed NCT00211198 Phase 4 ONTAK (denileukin difitox, DAB389IL-2)
36 Study Evaluating Two Dose Levels of Targretin Capsules in Patients With Refractory Cutaneous T-cell Lymphoma (CTCL) Completed NCT01007448 Phase 4 bexarotene;bexarotene
37 Doxorubicin Pharmacokinetics and Response in Non Hodgkin's Lymphoma Completed NCT00969462 Phase 4 Doxorubicin
38 Evaluation of Approved Weight-Based Dose Compared to Fixed Dose of Plerixafor in Patients With Non-Hodgkin's Lymphoma (NHL) Weighing Less Than 70 Kilograms Completed NCT01164475 Phase 4 Granulocyte-colony stimulating factor (G-CSF);Fixed Dose Plerixafor;Weight-Based Plerixafor
39 German Multicenter Trial for the Treatment of Newly Diagnosed T-lymphoblastic Lymphoma in Adults Completed NCT00199017 Phase 4 Dexamethasone/Prednisolone;Cyclophosphamide;Vincristine;Daunorubicin;Asparaginase;G-CSF;Mercaptopurine;Cytarabine;Methotrexate;VP16;Vindesine;Adriamycin;Thioguanine;HDARAC;Cladribine
40 Efficacy Response Duration and Toxicity of Rituximab, Fludarabine, and Cyclophosphamide (RFC) as 1st Line Treatment and Rituximab (R) in Maintenance Treatment in Follicular Non Hodgkin (FNH) Lymphoma Completed NCT01124526 Phase 4 Rituximab Fludarabine Cyclophosphamide
41 Whole Brain Irradiation in Primary Central Nervous System (CNS) Lymphoma (PCNSL) Completed NCT00153530 Phase 4 methotrexate
42 Comparison Of 2 Doses Of Temsirolimus (Torisel) In Patients With Mantle Cell Lymphoma Completed NCT01180049 Phase 4 temsirolimus;temsirolimus
43 Prophylactic Use of Entecavir for Non-Hodgkin's Lymphoma Patients With Resolved Hepatitis B Completed NCT00926757 Phase 4 Entecavir prophylaxis;Therapeutic entecavir
44 Carbohydrate Metabolism Disorder Frequency in Hypertriglyceridemia Induced by Bexarotene of Cutaneous T Cell Lymphoma Completed NCT01569724 Phase 4
45 An Expanded Access Program of Pegfilgrastim (Neulastim) in Participants With Non-Hodgkin's Lymphoma (NHL) Completed NCT02782845 Phase 4 Chemotherapy;Immunochemotherapy;Pegfilgrastim
46 LINFOTARGAM: Treatment With Chemotherapy Plus Rituximab and Highly Active Antiretroviral Therapy in Patients With Diffuse Large B Cell Lymphoma and Infection With the Human Immunodeficiency Virus (HIV) Completed NCT00466258 Phase 4 R-CHOP;Highly active antiretroviral therapy;Central nervous system (CNS) prophylaxis;Prophylaxis of opportunistic infections and support treatment
47 Study of ONTAK (Denileukin Diftitox) in Cutaneous T-Cell Lymphoma (CTCL) Patients Completed NCT00050999 Phase 4 ONTAK
48 Study of ONTAK (Denileukin Diftitox) in Previously Treated Cutaneous T-Cell Lymphoma Patients Completed NCT00051012 Phase 4 ONTAK
49 Effect of Rituximab on Immunological Recall Response to Specific Antigens in the Treatment of Non-Hodgkin's Lymphoma Completed NCT00090038 Phase 4 rituximab
50 Study of Rasburicase as Treatment or Prevention of Hyperuricemia Associated With Tumor Lysis Syndrome in Patients With Relapsed or Refractory Lymphoma, Leukemia, or Solid Tumor Malignancy Completed NCT00230217 Phase 4 Rasburicase (SR29142)

Search NIH Clinical Center for Lymphoma

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cochrane evidence based reviews: lymphoma

Sources

Genetic Tests for Lymphoma

About this section

Genetic tests related to Lymphoma:

# Genetic test Affiliating Genes
1 Lymphoma 30
Sources

Anatomical Context for Lymphoma

About this section

MalaCards organs/tissues related to Lymphoma:

42
B Cells, T Cells, Bone, Bone Marrow, Lung, Breast, Myeloid
Sources

Publications for Lymphoma

About this section

Articles related to Lymphoma:

(show top 50) (show all 45145)
# Title Authors Year
1
Diagnosis of acquired generalized lipodystrophy in a single patient with T-cell lymphoma and no exposure to Metreleptin. ( 30923630 )
2019
2
Acute disseminated encephalomyelitis due to JC virus infection as the onset of non-Hodgkin's lymphoma. ( 30337110 )
2019
3
Non-leukemic pediatric mixed phenotype acute leukemia/lymphoma: Genomic characterization and clinical outcome in a prospective trial for pediatric lymphoblastic lymphoma. ( 30578714 )
2019
4
Diffuse large B cell lymphoma primarily presenting as acute liver failure in a surviving patient. ( 31044044 )
2019
5
Non-Hodgkin lymphoma presenting as acute pancreatitis: A rare occurrence. ( 30656020 )
2019
6
Invited Commentary on "Spectral CT Imaging in the Differential Diagnosis of Small Bowel Adenocarcinoma From Primary Small Intestinal Lymphoma". ( 30967333 )
2019
7
Spectral CT Imaging in the Differential Diagnosis of Small Bowel Adenocarcinoma From Primary Small Intestinal Lymphoma. ( 30803898 )
2019
8
Cytomorphological Features of Lung Adenocarcinoma with Anaplastic Lymphoma Kinase Gene Rearrangement. ( 30745732 )
2019
9
A Comparative Study of Cell Block versus Biopsy for Detection of Epidermal Growth Factor Receptor Mutations and Anaplastic Lymphoma Kinase Rearrangement in Adenocarcinoma Lung. ( 30745733 )
2019
10
Epidermal growth factor receptor and anaplastic lymphoma kinase mutation in adenocarcinoma lung: Their incidence and correlation with histologic patterns. ( 30706855 )
2019
11
Anaplastic Lymphoma Kinase (ALK)-positive Tumors: Clinical, Radiographic and Molecular Profiles, and Uncommon Sites of Metastases in Patients With Lung Adenocarcinoma. ( 30741758 )
2019
12
Neuron-Specific Enolase Is an Independent Prognostic Factor in Resected Lung Adenocarcinoma Patients with Anaplastic Lymphoma Kinase Gene Rearrangements. ( 30673691 )
2019
13
Diffuse Large B-Cell Lymphoma With Striking Intrasinusoidal Pseudoglandular Growth Pattern as a Diagnostic Dilemma Mimicking Metastatic Poorly Differentiated Pancreatic Adenocarcinoma in an Intraabdominal Lymph Node. ( 30392418 )
2019
14
Outcome of patients receiving consolidative autologous peripheral blood stem cell transplantation in the frontline treatment of intravascular large B-cell lymphoma: Adult Lymphoma Working Group of the Japan Society for Hematopoietic Cell Transplantation. ( 30809035 )
2019
15
Appropriate radiation dose for symptomatic relief and local control in patients with adult T cell leukemia/lymphoma. ( 30124892 )
2019
16
The outcome and characteristics of patients with relapsed adult T cell leukemia/lymphoma after allogeneic hematopoietic stem cell transplantation. ( 30171618 )
2019
17
Clinical impact of the CONUT score and mogamulizumab in adult T cell leukemia/lymphoma. ( 30264165 )
2019
18
Epstein-Barr virus-related diffuse large B-cell lymphoma in mogamulizumab-treated adult T-cell leukemia with incomplete T-cell reconstitution. ( 30368656 )
2019
19
Clinical and histopathological significance of PD-1 expression in cutaneous lesions of adult T-cell leukemia-lymphoma. ( 30385085 )
2019
20
Thoracic manifestations of adult T-cell leukemia/lymphoma on chest CT: difference between clinical subtypes. ( 30582570 )
2019
21
Adult T-Cell Leukemia-Lymphoma. ( 30596217 )
2019
22
Human leukocyte antigen class II expression is a good prognostic factor of adult T-cell leukemia/lymphoma. ( 30630986 )
2019
23
Granuloma With an Underlying Lymphoma: A Diagnostic Challenge and a Wider Histologic Spectrum Including Adult T-Cell Leukemia/Lymphoma. ( 30653030 )
2019
24
Prognostic impact of soluble interleukin-2 receptor level profiling in smoldering type adult T-cell leukemia-lymphoma. ( 30656718 )
2019
25
Revised Adult T-Cell Leukemia-Lymphoma International Consensus Meeting Report. ( 30657736 )
2019
26
VCAP-AMP-VECP as a preferable induction chemotherapy in transplant-eligible patients with aggressive adult T-cell leukemia-lymphoma: a propensity score analysis. ( 30664725 )
2019
27
Clinical features at transformation in adult T-cell leukemia-lymphoma with smoldering and chronic types. ( 30680667 )
2019
28
JSH Practical Guidelines for Hematological Malignancies, 2018: II. Lymphoma-8. Adult T-cell leukemia-lymphoma. ( 30701465 )
2019
29
Safety and effectiveness of mogamulizumab in relapsed or refractory adult T-cell leukemia-lymphoma. ( 30740787 )
2019
30
Cytomegalovirus reactivation is associated with increased mortality more than 100 days after allogeneic hematopoietic stem cell transplantation for adult T-cell leukemia/lymphoma. ( 30773707 )
2019
31
Adult T-cell leukemia/lymphoma with conjunctival chemosis from infiltration and raised intraocular pressure. ( 30851797 )
2019
32
PAK Kinase Inhibition Has Therapeutic Activity in Novel Preclinical Models of Adult T-Cell Leukemia/Lymphoma. ( 30862694 )
2019
33
Crusted (Norwegian) scabies as a strong marker of adult T-cell leukemia/lymphoma in HTLV-1 infection. ( 30899475 )
2019
34
A Case of Adult T-Cell Leukemia/Lymphoma Complicated with Bilateral Chylothorax. ( 30911425 )
2019
35
Mogamulizumab for the Treatment of Adult T-cell Leukemia/Lymphoma. ( 30981611 )
2019
36
Lymphomatous Variant of Adult T-cell Leukemia/Lymphoma. ( 30983618 )
2019
37
Clinical Features, Pathological Features, and Treatment Outcomes of 22 Patients with Aggressive Adult T-cell Leukemia-lymphoma Treated with a Humanized CCR4 Antibody (Mogamulizumab) at a Single Institution during a 6-year Period (2012-2018). ( 30996180 )
2019
38
Molecular remissions are observed in chronic adult T cell leukemia/lymphoma in patients treated with mogamulizumab. ( 31004017 )
2019
39
Therapeutic Efficacy of Etretinate on Cutaneous-type Adult T-cell Leukemia-Lymphoma. ( 31017247 )
2019
40
Mogamulizumab treatment elicits autoantibodies attacking the skin in patients with adult T cell leukemia-lymphoma. ( 31018922 )
2019
41
Mogamulizumab versus investigator choice in relapsed/refractory adult T-cell leukemia/lymphoma: all four one or none for all? ( 31040231 )
2019
42
Identifying potential factors of variable response to mogamulizumab in adult T-cell leukemia/lymphoma between Japanese and other populations. ( 31040232 )
2019
43
Response to the comment: "Identifying potential factors of variable response to mogamulizumab in adult T-cell leukemia/lymphoma between Japanese and other populations". ( 31040233 )
2019
44
Flower cells of tropical descent: a challenging case of adult T-cell leukemia/lymphoma. ( 31041884 )
2019
45
RNA sequencing identifies clonal structure of T-cell repertoires in patients with adult T-cell leukemia/lymphoma. ( 31069115 )
2019
46
Plasma exchange following mogamulizumab therapy before bone marrow transplantation in refractory adult T-cell leukemia-lymphoma. ( 31104532 )
2019
47
Smoldering type adult T-cell leukemia/lymphoma effectively treated with mogamulizumab (anti-CC chemokine receptor 4 monoclonal antibody)-A case report. ( 31110745 )
2019
48
Impact of pretransplant central nervous system invasion in patients with aggressive adult T-cell leukemia lymphoma. ( 29899570 )
2019
49
Cytotoxic T-lymphocyte-associated antigen 4-positive aggressive adult T cell leukemia/lymphoma. ( 29978285 )
2019
50
Breast MALT lymphoma and AL amyloidosis complicating Sjögren's syndrome. ( 30975774 )
2019
Sources

Variations for Lymphoma

About this section

ClinVar genetic disease variations for Lymphoma:

6 (show all 20)
# Gene Variation Type Significance SNP ID Assembly Location
1 PTPN11 NM_002834.4(PTPN11): c.188A> G (p.Tyr63Cys) single nucleotide variant Pathogenic rs121918459 GRCh37 Chromosome 12, 112888172: 112888172
2 PTPN11 NM_002834.4(PTPN11): c.188A> G (p.Tyr63Cys) single nucleotide variant Pathogenic rs121918459 GRCh38 Chromosome 12, 112450368: 112450368
3 MYD88 NM_002468.5(MYD88): c.755T> C (p.Leu252Pro) single nucleotide variant Uncertain significance rs387907272 GRCh37 Chromosome 3, 38182641: 38182641
4 MYD88 NM_002468.5(MYD88): c.755T> C (p.Leu252Pro) single nucleotide variant Uncertain significance rs387907272 GRCh38 Chromosome 3, 38141150: 38141150
5 EZH2 NM_004456.4(EZH2): c.1937A> T (p.Tyr646Phe) single nucleotide variant Likely pathogenic rs267601394 GRCh37 Chromosome 7, 148508727: 148508727
6 EZH2 NM_004456.4(EZH2): c.1937A> T (p.Tyr646Phe) single nucleotide variant Likely pathogenic rs267601394 GRCh38 Chromosome 7, 148811635: 148811635
7 EZH2 NM_004456.4(EZH2): c.1937A> T (p.Tyr646Phe) single nucleotide variant Likely pathogenic rs267601394 NCBI36 Chromosome 7, 148139660: 148139660
8 EZH2 NM_004456.4(EZH2): c.1936T> C (p.Tyr646His) single nucleotide variant Likely pathogenic rs267601395 GRCh37 Chromosome 7, 148508728: 148508728
9 EZH2 NM_004456.4(EZH2): c.1936T> C (p.Tyr646His) single nucleotide variant Likely pathogenic rs267601395 GRCh38 Chromosome 7, 148811636: 148811636
10 EZH2 NM_004456.4(EZH2): c.1936T> C (p.Tyr646His) single nucleotide variant Likely pathogenic rs267601395 NCBI36 Chromosome 7, 148139661: 148139661
11 PMS2 NM_000535.6(PMS2): c.1831dup (p.Ile611Asnfs) duplication Pathogenic rs63750250 GRCh37 Chromosome 7, 6026565: 6026565
12 PMS2 NM_000535.6(PMS2): c.1831dup (p.Ile611Asnfs) duplication Pathogenic rs63750250 GRCh38 Chromosome 7, 5986934: 5986934
13 PMS2 NM_000535.6(PMS2): c.736_741delCCCCCTinsTGTGTGTGAAG (p.Pro246Cysfs) indel Pathogenic rs267608150 GRCh37 Chromosome 7, 6037019: 6037024
14 PMS2 NM_000535.6(PMS2): c.736_741delCCCCCTinsTGTGTGTGAAG (p.Pro246Cysfs) indel Pathogenic rs267608150 GRCh38 Chromosome 7, 5997388: 5997393
15 EZH2 NM_004456.4(EZH2): c.1936T> A (p.Tyr646Asn) single nucleotide variant Likely pathogenic rs267601395 GRCh37 Chromosome 7, 148508728: 148508728
16 EZH2 NM_004456.4(EZH2): c.1936T> A (p.Tyr646Asn) single nucleotide variant Likely pathogenic rs267601395 GRCh38 Chromosome 7, 148811636: 148811636
17 EZH2 NM_004456.4(EZH2): c.1937A> C (p.Tyr646Ser) single nucleotide variant Likely pathogenic rs267601394 GRCh37 Chromosome 7, 148508727: 148508727
18 EZH2 NM_004456.4(EZH2): c.1937A> C (p.Tyr646Ser) single nucleotide variant Likely pathogenic rs267601394 GRCh38 Chromosome 7, 148811635: 148811635
19 EZH2 NM_004456.4(EZH2): c.2045C> G (p.Ala682Gly) single nucleotide variant Likely pathogenic rs1057519833 GRCh37 Chromosome 7, 148506467: 148506467
20 EZH2 NM_004456.4(EZH2): c.2045C> G (p.Ala682Gly) single nucleotide variant Likely pathogenic rs1057519833 GRCh38 Chromosome 7, 148809375: 148809375

Copy number variations for Lymphoma from CNVD:

7 (show all 24)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 22797 1 168900 170100 Copy number Lymphoma
2 23565 1 171600 171900 Copy number Lymphoma
3 23675 1 172800 176700 Copy number Lymphoma
4 25326 1 187500 188100 Copy number Lymphoma
5 82146 14 105300 105900 Copy number Lymphoma
6 83536 14 21300 22200 Copy number Lymphoma
7 149232 2 88800 89400 Copy number Lymphoma
8 159014 21 39019555 39028514 Amplification KCNJ6 Lymphoma
9 159212 21 41403021 41411848 Amplification DSCAM Lymphoma
10 159621 21 43701285 43716936 Amplification ABCG1 Lymphoma
11 159656 21 43999157 44011961 Amplification SLC37A1 Lymphoma
12 159668 21 44081762 44094899 Amplification